The Alliance is an experienced multi-institutional cancer clinical trials group that has been reorganized in response to the Institute of Medicine (lOM) consensus report and NCI directives for cooperative group reorganization. Alliance provides a comprehensive and highly efficient clinical trials infrastructure, access to experienced collaborators across all disciplines of oncology clinical trials research, and a diverse portfolio f trials for patients with breast, gastrointestinal, genitourinary, respiratory, central nervous systm, hematological malignancies, and selected rare tumors. Particular strengths of the Alliance include the long-standing tradition of collaborative research of the legacy members, including many who have participated in cooperative group research since its inception in 1955. The Mission of the Alliance for Clinical Trials in Oncology is to reduce the impact of cancer by: - Conducting high quality multidisciplinary cancer control, prevention, and treatment trials that engage a comprehensive research network;- Furthering our understanding of the biological basis of the cancer process and its treatment;from discovery, to validation, to clinical practice;- Providing a scientific and operational infrastructure for innovative clinical and translational research in the academic and community settings.
To reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.
|Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16|
|Hatch, Ace J; Sibley, Alexander B; Starr, Mark D et al. (2016) Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med 5:2249-60|
|Johnston, Patrick B; LaPlant, Betsy; McPhail, Ellen et al. (2016) Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol 3:e309-16|
|Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91|
|Piccart-Gebhart, Martine; Holmes, Eileen; Baselga, JosÃ© et al. (2016) Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol 34:1034-42|
|Miller, Christopher A; Gindin, Yevgeniy; Lu, Charles et al. (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498|
|Salama, Joseph K; Gu, Lin; Wang, Xiaofei et al. (2016) Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). J Thorac Oncol 11:361-9|
|Phipps, Amanda I; Shi, Qian; Limburg, Paul J et al. (2016) Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. Int J Cancer 139:986-95|
|Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12|
|Giuliano, Armando E; Ballman, Karla; McCall, Linda et al. (2016) Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized T Ann Surg 264:413-20|
Showing the most recent 10 out of 64 publications